Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2005

View Archived Issues

XenoPort advances XP-19986 into phase I trials

Xcyte Therapies refocuses resources and activities

Arius' ARH-460-16-2 antibody to be studied for IBD

Keryx finalizes SPA agreement for KRX-101

PhG-alpha1 shows effectiveness on NSCLC cells in lab test

NIAID opens phase I study of experimental avian flu vaccine

Tanox to acquire Sunol's tissue factor antagonist program

Dyax updates DX-88 progress for HAE

Praecis in discussions regarding German Plenaxis submission

Enrollment completed in phase I/II CLL study of HuMax-CD20

NS-2359 advanced into phase II

IND accepted for MORAb-003

J&J and Guidant merger registration declared effective

CG-53135-05 shows no immunogenicity in patients with chemotherapy-induced mucositis

New evidence confirms the benefits of finasteride in the prevention of prostate cancer

Gene therapy claimed for the treatment of pain

A method for predicting colorectal cancer reported by Chiron

New treatments for cancer disclosed by Roche

New patents cover treatments for Alzheimer's disease

AZD-0865 effectively blocks acid output in preclinical tests

PHA-533533 displays a desirable anticancer preclinical profile

KMI-429 reduces beta-amyloid production in mice

VDM-11 produces antitussive effect in mice

12,14-Di-Cl-DHAA improves survival of postischemic myocytes

Approvable letter for Combidex

Takeda discontinues antidiabetic agent TAK-559

Enbrel launched in Japan

Eisai seeks European approval of Inovelon for Lennox-Gastaut Syndrome

Baraclude receives FDA approval

Zofran approved for children aged one month and older

Depo-subQ provera 104 approved for management of endometriosis pain

Once-monthly Boniva receives FDA approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...